Defence Innovation Challenge Awardee 2024
Our Partners
The problem
Brain Aneurysms - A Silent Threat
The silent killer striking every 18 minutes
M
K
%
%
high costs
&
Lack of preventive screening
Radiology overload and delays
High costs for the ecosystem
Uncertain treatment decisions
How it works
01
Suspected Aneurysm Diagnosis
02
Run CARA Risk Evaluation (non-invasive)
03
Triage based on CARA-derived risk profile
04
Post-treatment monitoring & predictive follow-up
Al-Powered Risk Scoring
Interpretable rupture prediction at point-of-care
Multimodal intelligence
Imaging + Hemodynamics + Clinical data fused
Workflow Automation
Reduces radiologist workload 50-70%
Longitudinal Monitoring
Tracks aneurysm changes over time
Proven Cost Savings
$60K-$80K per patient
Seamless EHR Integration
Epic-ready, clinician-friendly
Cloud-Native SaaS
Scalable, secure, enterprise-ready
Delivering measurable impact
Reduction in manual imaging workload
Reduction in manual imaging workload
Increase in diagnostic reliability
Reduction in unnecessary follow up scans
Key Insight
Creating an urgent demand for a comprehensive tool to enable early detection, accurate risk prediction, and personalized treatment.
Why now?
AI in Neurovascular care
$725B
In aggregate hospital bills over 10 years
$10B+
Annual spend in the USA alone
44%
Reduction in time to diagnosis & treatment
Flexible pricing
Flexible and customer centric business model
CARA’s pricing model is built to adapt to the needs of healthcare institutions of all sizes, offering flexibility, transparency, and value without disrupting existing workflows.
Strategic Partnerships
Collaborations with leading academic medical centers and stroke hospitals. Driving validation studies and early pilot programs with top clinicians.
Our pricing model includes
Competitive advantage
Why leading institutions choose CARA
CARA redefines neurovascular diagnostics and decision support, bridging clinical intelligence, workflow efficiency, and predictive analytics into a single platform built for the future of care.
Clinical Impact
CARA redefines neurovascular diagnostics by consolidating fragmented, labor-intensive protocols into an integrated, AI-driven framework that accelerates and standardizes neurovascular triage. Engineered for acute clinical settings, CARA’s decision support system synthesizes case-specific multimodal parameters to generate real-time, individualized prognostics on aneurysm rupture potential and trajectory. This enables clinicians to deliver evidence-based, timely interventions aligned with the highest standards of neurovascular care.
Value for Providers
CARA improves neurovascular care quality by integrating advanced imaging analytics and non-invasive hemodynamic insights to deliver precise, actionable triage scores. Our clinical decision engine empowers providers to rapidly tailor interventions, reducing unnecessary procedures and optimizing patient outcomes for aneurysm and stroke cases. Hospitals realize tangible value in enhanced care quality, streamlined workflows, and superior ROI enabled by secure, data-driven decision support that lowers costs and drives measurable operational improvement.
Technology Differentiators
CARA’s proprietary AI models, trained and validated across multiple clinical studies to ensure transparent, clinically reliable neurovascular triage. Our modular, interoperable architecture enables seamless integration with existing hospital systems and EHRs, allowing rapid, low-friction deployment in complex environments such as academic medical institutions and high-volume stroke centers. This dual emphasis on clinical evidence and enterprise grade compatibility delivers both trust and scalability, critical for health systems seeking transformative, future-proof care solutions with applied AI.
Industry Leadership
Backed by patented scientific innovations, robust clinical collaborations with NYU Langone and Bellevue, and a deep network of neurospecialists and researchers, CARA is positioned as the trusted partner for next-generation neurovascular care. Early adopters gain a strategic edge with accelerated diagnostics, personalized care pathways, optimized clinical resource utilization, and the ability to lead the adoption of precision-driven neurovascular medicine.
Solid IP moat through both patent protection and extensive peer-reviewed research
Achievements
Awards & Recognition
Founders Fellowship
2024
Stern Berkley Center for Entrepreneurship
2024, Semi Finalist
Tandon Future Labs
2024
NSF I-Corps + NYU Tech Venture Accelerator
2024
Brains behind CARA
“As a vascular neurologist specializing in the management of complex stroke and cerebrovascular cases, I see firsthand the urgent need for clinical tools that deliver actionable insights quickly and reliably. CARA’s platform has fundamentally transformed how we approach risk evaluation and triage. Its AI-driven analytics enable us to synthesize critical insights in real-time, creating a more personalized and efficient workflow for both routine and high-risk patients.”
Albert S. Favate MD
Division Chief Vascular Neurology, NYULH
Get in touch
Learn more about AneuView™️ today!
Non-invasive Predictive Scoring
Our Partners
